Servier And miRagen Therapeutics Extend Collaboration For The Research, Development And Commercialization Of Microrna-Targeting Drugs For Cardiovascular Disease
6/23/2014 8:26:32 AM
SURESNES, France & BOULDER, Colo.--(BUSINESS WIRE)--Servier, an independent French research-based pharmaceutical company with a significant presence in European and emerging markets, and miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that they have extended their research collaboration by two years to October 2016 to discover, develop, and commercialize drugs targeting microRNAs for cardiovascular disease. miRagen and Servier Research will continue preclinical research and development on multiple cardiovascular programs targeting microRNAs, including miR-208 and miR-15. Servier will lead the global clinical development and commercialization of microRNA therapeutic product candidates developed through the collaboration in all countries except the U.S. and Japan, where miRagen has retained all rights.
Help employers find you! Check out all the jobs and post your resume.
comments powered by